



## UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NUMBER	FILING OR 371 (c) DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
10/764,418	01/23/2004	Jannis G. Stavrianopoulos	Enz-61(D11)

CONFIRMATION NO. 8199

## FORMALITIES LETTER



\*OC000000012376485\*

Ronald C. Fedus, Esq.  
Enzo Life Sciences, Inc.  
c/o Enzo Biochem, Inc.  
527 Madison Avenue (9th Floor)  
New York, NY 10022-4304

Date Mailed: 04/16/2004

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS  
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

*Filing Date Granted*

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 CFR. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

**For questions regarding compliance to these requirements, please contact:**

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at [patin21help@uspto.gov](mailto:patin21help@uspto.gov) or [patin3help@uspto.gov](mailto:patin3help@uspto.gov)

Replies should be mailed to: Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450

Alexandria VA 22313-1450

---

*A copy of this notice MUST be returned with the reply.*

Y. G.

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

4-21-04

Enz-61(D11)



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Stavrianopolous et al

Serial No. 10/764,418

Filed: January 23, 2004

Title: **PROCESS FOR DETECTING THE PRESENCE  
OR QUANTITY OF ENZYMATIC ACTIVITY  
IN A SAMPLE**

Group Art Unit: Not yet known

Examiner: Not yet determined

527 Madison Avenue, 9<sup>th</sup> Floor  
New York, New York 10022  
April 20, 2004

**FILED VIA EXPRESS MAIL**

Mail Stop Missing Parts  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**COMMUNICATION DIRECTED TO NOTICE TO COMPLY WITH  
REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING  
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE  
DISCLOSURES**

Dear Sirs:

This Communication is directed to the Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures ("Notice") that was mailed on April 16, 2004 in connection with the above-identified application. A copy of the Notice is attached hereto as Exhibit A.

Enz-61(D11)

Stavrianopolous, et al  
Serial No.: 10/764,418  
Filed: January 23, 2004  
Page 2 [Communication – April 20, 2004]

---

**EXPRESS MAIL CERTIFICATE**

"Express Mail" Label No.: EV063168957US

Deposit Date: April 20, 2004

I hereby certify that this paper and the attachments herein are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.110 on the date indicated above and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Ronald C. Fedus  
Reg. No. 32,567

APRIL 20 2004  
Date

In response to the Notice, Applicants hereby submit the following documents or items:


1. an initial paper copy of the "Sequence Listing" (Exhibit 1)
2. Amendment directing entry of the "Sequence Listing" into the specification (Exhibit 2)
3. a Statement Under 37 CFR 1.821(f) attesting that the content of the paper is the same as the computer readable form submitted in the parent application, Serial No. 10/096,075, on February 3, 2003 (Exhibit 3)
4. a Statement to Support Filing and Submission in Accordance with 37 CFR 1.821-1.825 (Exhibit 4).

No fee is believed due in connection with this Communication or the documents or items submitted herewith. If any fee or fees are due, however, the Patent and Trademark Office is hereby authorized to charge the amount of any such fee to Deposit Account 05-1135, or to credit any overpayment thereto.

Stavrianopolous, et al  
Serial No.: 10/764,418  
Filed: January 23, 2004  
Page 4 [Communication – April 20, 2004]

If helpful in processing this Communication, the undersigned may be contacted by telephone at (212) 583-0100 during business hours.

Respectfully submitted,



Ronald C. Fedus  
Registration No. 32,567  
Natalie Bogdanos  
Registration No. 51,480  
Attorneys for Applicants

ENZO LIFE SCIENCES, INC.  
c/o Enzo Biochem, Inc.  
527 Madison Avenue, 9<sup>th</sup> Floor  
New York, New York 10022  
Tel. (212) 583-0100